By Eric Sagonowsky
After a very public back-and-forth over COVID-19 vaccine supplies in Europe earlier this year, AstraZeneca said it would aim to deliver 40 million doses in the first quarter. It’s now rolling the estimate back to 30 million, Reuters reports—the same figure that triggered the initial controversy. Meanwhile, in some countries, doses are going unused.
read more
By Paige Minemyer
The research team at UHG has rolled out a slew of projects over the past year in response to the pandemic, ranging from studies on COVID therapies to home health to protective equipment.
read more
By Eric Sagonowsky
As the COVID-19 pandemic reshaped the global economy, some pharma companies coped better than others, and the who and why offer some hints about who's best suited to weather a future crisis. That's the word from Jefferies analysts, who identified some pitfalls—and some boons—for drugmakers on pandemic time.
read more
By Ben Adams
Sanofi doubled down on its original 2018 pact with Translate Bio last year as the pair teamed up for an mRNA approach to COVID vaccines, and today the two announced they are starting clinical trials using the tech.
read more
By Robert King
President Biden on Thursday signed into law a $1.9 trillion COVID-19 relief package that boosts ACA subsidies and gives more money to rural hospitals, sending the legislation to President Joe Biden for his signature.
read more
By Conor Hale
The health-tech company ixlayer has raised $75 million to support its telehealth platform for connecting laboratory diagnostics with the people who need them on a large scale.
read more
By Eric Sagonowsky
Thanks to the success of its COVID-19 vaccine, the drug giant Pfizer has become a household name around the globe—and the company's eyeing $15 billion in sales from the shot this year. For his work steering the ship through 2020, CEO Albert Bourla collected a pay package worth more than $21 million.
read more
By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale
AstraZeneca has again lowered its vaccine supply estimate to Europe. After a successful year dealing with COVID-19, Pfizer rewarded CEO Albert Bourla with more than $21 million. Jefferies reviews the response of pharma companies to the pandemic. Novavax vaccine 100% effective protection vs. severe COVID-19 cases. Altimmune, Lonza expand vaccine agreement.
read more
